Pulmonx Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steve Williamson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Nov 08

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Aug 02

Pulmonx: Interesting Technology But Struggling With Adoption

Jul 02

These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Feb 28

CEO

Steve Williamson (50 yo)

less than a year

Permanencia

Mr. Steven S. Williamson, also known as Steve, serves as CEO, President & Director of Pulmonx Corporation since March 15, 2024. He was Chief Commercial Officer of Outset Medical, Inc. since November 2020 u...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Lehman	General Counsel & Secretary	3.6yrs	US$2.64m	0.092% $ 300.8k
Geoffrey Rose	Chief Commercial Officer	4.3yrs	US$1.96m	0.41% $ 1.3m
Steven Williamson	CEO, President & Director	less than a year	sin datos	sin datos
Mehul Joshi	Chief Financial Officer	less than a year	sin datos	sin datos
Sri Radhakrishnan	Chief Technical Officer	4.3yrs	sin datos	sin datos
Marcee Maroney	Vice President of Marketing	no data	sin datos	sin datos
Sarah Huber	Vice President of Sales (U.S.)	2.3yrs	sin datos	sin datos
Lisa Paul	Chief People Officer	2.3yrs	sin datos	sin datos
Jérôme Erath	Senior VP & GM of Europe Middle-East & Africa	no data	sin datos	sin datos
John McKune	VP & Corporate Controller	less than a year	sin datos	0.050% $ 164.3k

2.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LUNG se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Williamson	CEO, President & Director	less than a year	sin datos	sin datos
Dana Mead	Independent Chairperson of the Board	14.3yrs	US$228.21k	0.10% $ 326.3k
Richard Ferrari	Independent Director	17.3yrs	US$213.21k	0.077% $ 252.6k
Glendon French	Director	9.4yrs	US$5.80m	2.42% $ 7.9m
Georgia Garinois-Melenikiotou	Independent Director	3.7yrs	US$213.21k	0.089% $ 292.0k
Thomas Burns	Independent Director	3.7yrs	US$200.71k	0.022% $ 70.7k
Daniel Florin	Independent Director	4.3yrs	US$220.71k	0.075% $ 243.2k
Alissa Lynch	Independent Director	2.8yrs	US$203.21k	0.027% $ 87.3k
Tiffany Sullivan	Independent Director	2.8yrs	US$198.21k	0.022% $ 73.0k

3.7yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de LUNG se considera experimentada (3.6 años de antigüedad promedio).

Pulmonx Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pulmonx Corporation, Annual General Meeting, May 16, 2024

Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024

Pulmonx Corporation Announces Chief Executive Officer, Effective March 15, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Recent updates

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation to Report Q1, 2024 Results on May 01, 2024

Pulmonx Corporation, Annual General Meeting, May 16, 2024

Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024

Pulmonx: Revisiting Thesis Following Management Change

Consensus EPS estimates fall by 13%, revenue upgraded

Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Pulmonx Corporation Announces Chief Executive Officer, Effective March 15, 2024

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation to Report Q4, 2023 Results on Feb 21, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$69k worth of stock

Price target decreased by 12% to US$14.83

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation Provides Earnings Guidance for 2023

Pulmonx Corporation to Report Q3, 2023 Results on Oct 30, 2023

Pulmonx Corporation Announces Chief Financial Officer Changes

CEO, President & Director recently sold US$65k worth of stock

Price target increased by 7.4% to US$15.57

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation Updates Revenue Guidance for Fiscal Year 2023

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation to Report Q2, 2023 Results on Aug 02, 2023

Price target increased by 9.1% to US$14.50

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$75k worth of stock

Pulmonx Corporation Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$12.43

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation to Report Q4, 2022 Results on Feb 22, 2023

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Price target decreased to US$13.07

High number of new directors

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.28 loss in 3Q 2021)

Pulmonx Corporation Revises Earnings Guidance for the Full Year of 2022

Pulmonx Corporation to Report Q3, 2022 Results on Nov 03, 2022

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation Announces the Presentation of Interim Results from the Convert Study At the 2022 European Respiratory Society (Ers) International Conference

CEO, President & Director recently sold US$53k worth of stock

CEO, President & Director notifies of intention to sell stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2022

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Pulmonx Corporation to Report Q2, 2022 Results on Aug 02, 2022

Price target decreased to US$28.00

Pulmonx: Interesting Technology But Struggling With Adoption

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2022

High number of new directors

Pulmonx Corporation to Report Q1, 2022 Results on May 03, 2022

Pulmonx Corporation, Annual General Meeting, May 26, 2022

Consensus revenue estimates fall by 22%

These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$38.33

Pulmonx Corporation Provides Revenue Guidance for the First Quarter and Full Year 2022

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation to Report Q4, 2021 Results on Feb 23, 2022

CEO, President & Director notifies of intention to sell stock

Price target decreased to US$49.33

Chief Financial Officer notifies of intention to sell stock